Kirkland & Ellis has strengthened its litigation practice by bringing over a group of mass tort attorneys from Orrick, Herrington & Sutcliffe, a move that signals the firm’s intent to deepen its bench in complex multi-plaintiff and multidistrict litigation. Lateral hires of this kind are how large defense-side firms rapidly acquire specialized expertise without building it internally over years, and mass tort work — which spans product liability, pharmaceutical, environmental, and consumer-harm cases — is an area where seasoned trial and coordination experience commands a premium. For people following class actions and mass torts, the takeaway is straightforward: the lawyers most companies hire to defend against large coordinated claims are concentrating at a handful of elite firms, and Kirkland is positioning itself as one of the dominant players.
A practical example of why this matters: in sprawling MDLs like the ones over talc, opioids, or PFAS “forever chemicals,” the firm representing corporate defendants often shapes settlement structure, bellwether trial strategy, and how quickly claimants see money. When the defense bench gets stronger, plaintiffs’ counsel face more sophisticated opposition. This article explains what the hires mean, why mass tort talent is in demand, and how shifts in the defense bar ripple out to ordinary claimants in settlements.
Table of Contents
- Why Did Kirkland Expand Its Litigation Bench With Mass Tort Hires From Orrick?
- What Mass Tort Litigation Experience Actually Brings to a Firm
- How Lateral Moves Reshape the Defense Bar
- What This Means for Claimants in Active Settlements
- The Limits and Risks of Reading Too Much Into Big Law Hires
- How Defense-Side Strength Compares to the Plaintiffs’ Bar
- Where Mass Tort Litigation Is Concentrating
- Frequently Asked Questions
Why Did Kirkland Expand Its Litigation Bench With Mass Tort Hires From Orrick?
Kirkland’s expansion reflects a basic supply-and-demand reality in Big Law: mass tort and product liability litigation has grown steadily, and the lawyers who can manage thousand-plaintiff dockets, coordinate science-heavy expert discovery, and negotiate global settlements are scarce. Pulling a team from Orrick lets Kirkland absorb an established practice group, including the client relationships and institutional knowledge those attorneys carry, rather than recruiting individuals piecemeal. The strategic logic mirrors what other firms have done.
When a defense-side practice migrates as a unit, the receiving firm typically gains an immediate book of business — corporate clients facing pending or anticipated litigation. Compare this to organic growth, where a firm might spend a decade training associates into trial-ready mass tort partners; a lateral acquisition compresses that timeline to a single hiring cycle. For Orrick, losing a mass tort group is a reminder that practice areas at large firms are mobile and can hollow out quickly. A firm known for a particular litigation specialty one year can see that reputation walk out the door the next, which is why retention of star partners is a constant pressure in the industry.
What Mass Tort Litigation Experience Actually Brings to a Firm
Mass tort litigation is distinct from a single-plaintiff lawsuit or even a traditional class action. It often involves thousands of individual claims consolidated for pretrial purposes in a multidistrict litigation, where each plaintiff retains a separate case but shares common discovery and bellwether trials. Attorneys who specialize here must juggle epidemiology, regulatory history, causation experts, and the logistics of managing enormous claimant pools — skills that do not transfer automatically from general commercial litigation. The warning for observers is that concentrating this expertise on the defense side can lengthen and complicate cases for plaintiffs.
Experienced defense teams are adept at challenging general and specific causation, narrowing the pool of compensable claimants, and structuring settlements with conditions — such as requiring medical records, lien resolution, or proof-of-use documentation — that delay payouts. A stronger defense bench does not necessarily mean fairer outcomes; it can mean more procedural hurdles. There is also a limitation worth noting: prestige hires do not guarantee courtroom results. A firm can assemble an impressive roster and still lose key bellwether trials, which historically have driven defendants toward settlement. Talent reduces risk for corporate clients but does not eliminate the underlying liability exposure when the underlying science or documents are damaging.
How Lateral Moves Reshape the Defense Bar
Lateral partner movement among elite firms has accelerated over the past decade, and litigation groups are among the most frequently poached. When a mass tort team moves to a firm like Kirkland, it can trigger conflicts-of-interest reshuffling: the receiving firm may have to decline new matters that clash with the incoming group’s existing clients, and some clients may follow the lawyers while others stay behind. A concrete example of how this plays out: in the opioid litigation, defense representation was spread across several national firms, and as partners moved between firms, client assignments and co-counsel arrangements shifted accordingly.
Companies facing parallel suits in multiple jurisdictions often want continuity, so they may move their business to keep the same lead attorneys — meaning a single hire can redirect millions of dollars in legal fees. These moves also affect plaintiffs’ firms indirectly. Plaintiff-side mass tort shops calibrate strategy around who they expect to face across the table. A change in defense counsel can alter settlement timing, the aggressiveness of motion practice, and whether a case heads toward trial or early resolution.
What This Means for Claimants in Active Settlements
For someone with a claim in a mass tort or class action, the identity of defense counsel rarely changes whether they qualify, but it can affect how the process unfolds. A well-resourced defense team may push for stricter eligibility criteria, more documentation, and tighter audits of claims — measures designed to weed out unsupported filings but which also slow legitimate claimants’ payments. The tradeoff cuts both ways.
Sophisticated defense firms sometimes prefer comprehensive global settlements to the uncertainty of repeated trials, which can mean faster resolution for the overall litigation. Compare a scenario where a defendant digs in and litigates every bellwether for years against one where experienced counsel negotiates a structured settlement fund early: claimants in the latter may receive money sooner, even if individual awards are scrutinized more closely. The practical advice for claimants is to focus on what they control — keeping thorough records, meeting filing deadlines, and working with qualified plaintiff-side counsel — rather than on which firm represents the defendant. The defense bench is largely outside a claimant’s influence, but documentation quality directly affects whether a claim survives review.
The Limits and Risks of Reading Too Much Into Big Law Hires
It is easy to overinterpret a high-profile lateral move. A firm adding mass tort partners does not mean a wave of new litigation is coming, nor does it predict outcomes in any specific case. Hiring decisions are driven by business development, partner economics, and internal succession planning as much as by any forecast about litigation trends. A warning for anyone following these stories for investment or strategic signals: law firm press releases and trade coverage emphasize prestige and capability, but they rarely disclose the financial terms, client portability, or whether the move resolves an internal conflict.
The actual impact on a given litigation may not surface for years, if at all, and some celebrated hires quietly underperform. There is also a structural limitation. No single firm controls a mass tort; MDLs involve plaintiffs’ steering committees, court-appointed leadership, special masters, and often dozens of defense firms representing different defendants. Kirkland’s strengthened bench is one input among many, and judges retain significant control over case management, discovery scope, and settlement approval.
How Defense-Side Strength Compares to the Plaintiffs’ Bar
The plaintiffs’ mass tort bar operates on a different economic model — contingency fees funded by litigation financing and advertising spend — while defense firms bill hourly to corporate clients with deep pockets. This asymmetry shapes the contest.
A strong defense bench at a firm like Kirkland is matched against well-capitalized plaintiffs’ firms that invest heavily in client intake and expert development. For example, in litigation over products like Roundup or certain medical devices, plaintiffs’ firms have funded extensive scientific testing and run national advertising campaigns to build claimant inventories, while defendants countered with elite trial teams. The balance of talent and resources on both sides often determines whether a defendant settles or fights, and a single firm’s hiring spree is just one factor in that equation.
Where Mass Tort Litigation Is Concentrating
Mass tort and product liability work has clustered around active dockets in areas such as PFAS contamination, talc-related claims, social media harm to minors, and pharmaceutical injury suits. These categories share features that attract specialized firms: large potential claimant pools, contested scientific causation, and the prospect of multibillion-dollar exposure that justifies premium legal spending on both sides.
A concrete marker of this concentration is the federal MDL system itself, where a small number of district courts host the largest consolidated proceedings. The Judicial Panel on Multidistrict Litigation centralizes related federal suits before a single judge, and the firms with the deepest mass tort benches tend to appear repeatedly across these dockets — which is precisely the kind of repeat-player advantage a firm gains by adding an established practice group.
Frequently Asked Questions
What is a mass tort, and how is it different from a class action?
A mass tort involves many individuals harmed by the same product or conduct, but each keeps a separate lawsuit, often consolidated in an MDL for pretrial efficiency. A class action treats claimants as a single group represented collectively. Mass tort plaintiffs typically receive individualized awards based on their specific injuries.
Does a stronger defense firm hurt my chances in a settlement?
Not directly. Your eligibility depends on the settlement’s criteria and your documentation. A well-resourced defense team may push for stricter proof and audits, which can slow payments, but it does not change whether you have a valid claim.
Why do law firms hire entire practice groups instead of individual lawyers?
Hiring a group brings established client relationships, institutional knowledge, and immediate capacity, compressing what would otherwise take years to build. It also lets the firm enter or deepen a practice area quickly.
Will this hire affect cases that are already pending?
Possibly in terms of strategy and timing, but the structure of an MDL — with court-appointed leadership, multiple defense firms, and judicial oversight — limits how much any single firm’s roster changes the trajectory.
How can I protect my claim regardless of who represents the defendant?
Keep thorough records, meet all filing deadlines, preserve proof of product use and medical treatment, and work with qualified plaintiff-side counsel. Documentation quality is what most often determines whether a claim survives review.